EGFR and non-small cell lung carcinoma: In Thailand, there are also issues related to reimbursement for this mode of therapy in patients with EGFR-positive NSCLC, since the CSMBS does not cover the cost of EGFR-TKI for first-line treatment, only second- or later-line treatment.